Categories Earnings, Health Care

Regeneron Pharmaceuticals (REGN): Q4 2019 Earnings Snapshot

— Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q4 2019 earnings of $7.50 per share, vs. $6.92 expected.

— Revenues grew 13% to $2.17 billion, vs. $2.11 billion expected.

Regeneron reports Q4 2019 earnings results

— Net product sales were $1.28 billion.

— EYLEA net product sales in the US were $1.22 billion.

— Sanofi and Bayer collaboration revenues were $748 million.

— R&D expenses totaled $683 million.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

360 DigiTech (NASDAQ: QFIN) Q3 2021 Research Summary

The positive effects of widespread digitalization and e-commerce growth on China’s financial services industry became more pronounced during the pandemic as the movement restrictions drove more retail customers to online

Activision Blizzard (ATVI): Three reasons why this stock deserves to be on your radar

Shares of Activision Blizzard Inc. (NASDAQ: ATVI) were up 1.6% on Thursday. The stock has dropped 14% since the start of the year. The company has been in the news

IPO Alert: Here’s all you need to know about Remitly Global’s upcoming market debut

The emergence of technology-driven financial services is making people think beyond conventional banks when it comes to availing loans and transferring funds. In a move aimed at taking its business

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top